Your request to link to rcsb for Mitogen-activated protein kinase 14

---

• 1DI9: the structure of p38 mitogen-activated protein kinase in complex with 4-[3-methylsulfanylanilino]-6,7- dimethoxyquinazoline (10.1021/JM990401T )
• 1IAN: human p38 map kinase inhibitor complex (10.1038/NSB0497-311 )
• 1KV1: p38 map kinase in complex with inhibitor 1 (10.1038/NSB770 )
• 1KV2: human p38 map kinase in complex with birb 796 (10.1038/NSB770 )
• 1LEW: crystal structure of map kinase p38 complexed to the docking site on its nuclear substrate mef2a (10.1016/S1097-2765(02)00525-7 )
• 1LEZ: crystal structure of map kinase p38 complexed to the docking site on its activator mkk3b (10.1016/S1097-2765(02)00525-7 )
• 1M7Q: crystal structure of p38 map kinase in complex with a dihydroquinazolinone inhibitor (10.1016/S0960-894X(02)00752-7 )
• 1OUK: the structure of p38 alpha in complex with a pyridinylimidazole inhibitor (10.1038/NSB949 )
• 1OUY: the structure of p38 alpha in complex with a dihydropyrido-pyrimidine inhibitor (10.1038/NSB949 )
• 1OVE: the structure of p38 alpha in complex with a dihydroquinolinone (10.1038/NSB949 )
• 1OZ1: p38 mitogen-activated kinase in complex with 4-azaindole inhibitor (10.1021/JM0301787 )
• 1R39: the structure of p38alpha (10.1016/J.BBAPAP.2003.09.009 )
• 1R3C: the structure of p38alpha c162s mutant (10.1016/J.BBAPAP.2003.09.009 )
• 1W7H: p38 kinase crystal structure in complex with small molecule inhibitor (10.1021/JM0495778 )
• 1W82: p38 kinase crystal structure in complex with small molecule inhibitor (10.1021/JM049575N )
• 1W83: p38 kinase crystal structure in complex with small molecule inhibitor (10.1021/JM049575N )
• 1W84: p38 kinase crystal structure in complex with small molecule inhibitor (10.1021/JM049575N )
• 1WBN: fragment based p38 inhibitors (10.1021/JM049575N )
• 1WBO: fragment based p38 inhibitors (10.1021/JM0495778 )
• 1WBS: identification of novel p38 alpha map kinase inhibitors using fragment-based lead generation. (10.1021/JM049575N )
• 1WBT: identification of novel p38 alpha map kinase inhibitors using fragment-based lead generation. (10.1021/JM049575N )
• 1WBV: identification of novel p38 alpha map kinase inhibitors using fragment-based lead generation. (10.1021/JM049575N )
• 1WBW: identification of novel p38 alpha map kinase inhibitors using fragment-based lead generation. (10.1021/JM049575N )
• 1WFC: structure of apo, unphosphorylated, p38 mitogen activated protein kinase p38 (p38 map kinase) the mammalian homologue of the yeast hog1 protein (10.1074/JBC.271.44.27696 )
• 1YQJ: crystal structure of p38 alpha in complex with a selective pyridazine inhibitor (10.1016/J.BMCL.2005.02.010 )
• 1YW2: mutated mus musculus p38 kinase (mp38) (10.1016/J.BMCL.2005.02.066 )
• 1YWR: crystal structure analysis of inactive p38 kinase domain in complex with a monocyclic pyrazolone inhibitor (10.1016/J.BMCL.2005.03.007 )
• 1ZYJ: human p38 map kinase in complex with inhibitor 1a (10.1016/J.BMCL.2005.08.038 )
• 1ZZ2: two classes of p38alpha map kinase inhibitors having a common diphenylether core but exhibiting divergent binding modes (10.1016/J.BMCL.2005.08.038 )
• 1ZZL: crystal structure of p38 with triazolopyridine (10.1021/JM050346Q )
• 2BAJ: p38alpha bound to pyrazolourea (10.1021/BI051714V )
• 2BAK: p38alpha map kinase bound to mpaq (10.1021/BI051714V )
• 2BAL: p38alpha map kinase bound to pyrazoloamine (10.1021/BI051714V )
• 2BAQ: p38alpha bound to ro3201195 (10.1021/BI051714V )
• 2EWA: dual binding mode of pyridinylimidazole to map kinase p38 (10.1002/ANIE.200502770 )
• 2FSL: mitogen activated protein kinase p38alpha (d176a+f327s) activating mutant form-a (10.1016/J.JMB.2006.08.043 )
• 2FSM: mitogen activated protein kinase p38alpha (d176a+f327s) activating mutant form-b (10.1016/J.JMB.2006.08.043 )
• 2FSO: mitogen activated protein kinase p38alpha (d176a) activating mutant (10.1016/J.JMB.2006.08.043 )
• 2FST: mitogen activated protein kinase p38alpha (d176a+f327l) activating mutant (10.1016/J.JMB.2006.08.043 )
• 2GFS: p38 kinase crystal structure in complex with ro3201195 (10.1021/JM050736C )
• 2GHL: mutant mus musculus p38 kinase domain in complex with inhibitor pg- 874743 (10.1016/J.BMCL.2006.03.095 )
• 2GHM: mutated map kinase p38 (mus musculus) in complex with inhbitor pg- 895449 (10.1016/J.BMCL.2006.03.095 )
• 2GTM: mutated mouse p38 map kinase domain in complex with inhibitor pg- 892579 (10.1016/J.BMCL.2006.05.050 )
• 2GTN: mutated map kinase p38 (mus musculus) in complex with inhbitor pg- 951717 (10.1016/J.BMCL.2006.05.050 )
• 2I0H: the structure of p38alpha in complex with an arylpyridazinone (10.1016/J.BMCL.2006.08.074 )
• 2LGC: joint nmr and x-ray refinement reveals the structure of a novel dibenzo[a,d]cycloheptenone inhibitor/p38 map kinase complex in solution (10.1002/ANIE.201105241 )
• 2NPQ: a novel lipid binding site in the p38 alpha map kinase (10.1016/J.JMB.2007.09.002 )
• 2OKR: crystal structure of the p38a-mapkap kinase 2 heterodimer (10.1074/JBC.M611165200 )
• 2ONL: crystal structure of the p38a-mapkap kinase 2 heterodimer (10.1074/JBC.M611165200 )
• 2OZA: structure of p38alpha complex (10.1073/PNAS.0701679104 )
• 2PUU: crystal structure of p38 complex with 1-(5-tert-butyl-2-p-tolyl-2h- pyrazol-3-yl)-3-[4-(6-morpholin-4-ylmethyl-pyridin-3-yl)naphthalen-1- yl]urea
• 2QD9: p38 alpha map kinase inhibitor based on heterobicyclic scaffolds (10.1016/J.BMCL.2007.07.029 )
• 2RG5: phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11b (10.1021/JM7009414 )
• 2RG6: phenylalanine pyrrolotriazine p38 alpha map kinase inhibitor compound 11j (10.1021/JM7009414 )
• 2Y8O: crystal structure of human p38alpha complexed with a mapk docking peptide (10.1126/SCISIGNAL.2003004 )
• 2YIS: triazolopyridine inhibitors of p38 kinase. (10.1021/JM200677B )
• 2YIW: triazolopyridine inhibitors of p38 kinase (10.1021/JM200677B )
• 2YIX: triazolopyridine inhibitors of p38 (10.1021/JM200677B )
• 2ZAZ: crystal structure of p38 in complex with 4-anilino quinoline inhibitor (10.1016/J.BMCL.2007.10.076 )
• 2ZB0: crystal structure of p38 in complex with biphenyl amide inhibitor (10.1016/J.BMCL.2007.10.076 )
• 2ZB1: crystal structure of p38 in complex with biphenyl amide inhibitor (10.1016/J.BMCL.2007.10.076 )
• 3BV2: morpholino pyrrolotriazine p38 alpha map kinase inhibitor compound 30 (10.1016/J.BMCL.2008.02.067 )
• 3BV3: morpholino pyrrolotriazine p38 alpha map kinase inhibitor compound 2 (10.1016/J.BMCL.2008.02.067 )
• 3BX5: p38 alpha map kinase complexed with bms-640994 (10.1016/J.BMCL.2008.02.031 )
• 3C5U: p38 alpha map kinase complexed with a benzothiazole based inhibitor (10.1016/J.BMCL.2008.02.011 )
• 3CTQ: structure of map kinase p38 in complex with a 1-o-tolyl-1,2, 3-triazole-4-carboxamide (10.1016/J.BMCL.2008.04.043 )
• 3D7Z: crystal structure of p38 kinase in complex with a biphenyl amide inhibitor (10.1016/J.BMCL.2008.06.048 )
• 3D83: crystal structure of p38 kinase in complex with a biphenyl amide inhibitor (10.1016/J.BMCL.2008.06.028 )
• 3DS6: p38 complex with a phthalazine inhibitor (10.1021/JM8005417 )
• 3DT1: p38 complexed with a quinazoline inhibitor (10.1021/JM8005417 )
• 3E92: crystal structure of p38 kinase in complex with a biaryl amide inhibitor (10.1016/J.BMCL.2008.08.051 )
• 3E93: crystal structure of p38 kinase in complex with a biaryl amide inhibitor (10.1016/J.BMCL.2008.08.051 )
• 3FC1: crystal structure of p38 kinase bound to pyrimido-pyridazinone inhibitor (10.1021/JM050306M )
• 3FI4: p38 kinase crystal structure in complex with ro4499
• 3FKL: p38 kinase crystal structure in complex with ro9552
• 3FKN: p38 kinase crystal structure in complex with ro7125
• 3FKO: p38 kinase crystal structure in complex with ro3668
• 3FL4: p38 kinase crystal structure in complex with ro5634
• 3FLN: p38 kinase crystal structure in complex with r1487
• 3FLQ: p38 kinase crystal structure in complex with 6-(2,4-difluoro-phenoxy)- 2-((s)-2-methanesulfonyl-1-methyl-ethylamino)-8-methyl-8h-pyrido[2,3- d]pyrimidin
• 3FLS: p38 kinase crystal structure in complex with 6-(2,4-difluoro-phenoxy)- 2-((r)-2-methanesulfonyl-1-methyl-ethylamino)-8-methyl-8h-pyrido[2,3- d]pyrimidin-7-one
• 3FLW: p38 kinase crystal structure in complex with pamapimod
• 3FLY: p38 kinase crystal structure in complex with 6-(2,4-difluoro-phenoxy)- 2-isopropylamino-8-methyl-8h-pyrido[2,3-d]pyrimidin-7-one
• 3FLZ: p38 kinase crystal structure in complex with 8-methyl-6-phenoxy-2- (tetrahydro-pyran-4-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one
• 3FMH: p38 kinase crystal structure in complex with 6-(2,4-difluoro-phenoxy)- 8-methyl-2-((r)-1-methyl-2-tetrazol-2-yl-ethylamino)-8h-pyrido[2,3- d]pyrimidin-7-one
• 3FMJ: p38 kinase crystal structure in complex with 4-(5-methyl-3-phenyl- isoxazol-4-yl)-pyrimidin-2-ylamine
• 3FMK: p38 kinase crystal structure in complex with 6-(2,4-difluoro-phenoxy)- 8-methyl-2-((s)-1-methyl-2-tetrazol-2-yl-ethylamino)-8h-pyrido[2,3- d]pyrimidin-7-one
• 3FML: p38 kinase crystal structure in complex with ro6224
• 3FMM: p38 kinase crystal structure in complex with ro6226
• 3FMN: p38 kinase crystal structure in complex with ro2530
• 3FSF: p38 kinase crystal structure in complex with 3-(2,6- dichloro-phenyl)-7-[4-(2-diethylamino-ethoxy)-phenylamino]- 1-methyl-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one
• 3FSK: p38 kinase crystal structure in complex with ro6257
• 3GC7: the structure of p38alpha in complex with a dihydroquinazolinone (10.1107/S090744490901600X )
• 3GCP: human p38 map kinase in complex with sb203580 (10.1021/JA902010P )
• 3GCQ: human p38 map kinase in complex with rl45 (10.1021/JA902010P )
• 3GCS: human p38 map kinase in complex with sorafenib (10.1021/JA902010P )
• 3GCU: human p38 map kinase in complex with rl48 (10.1021/JA902010P )
• 3GCV: human p38 map kinase in complex with rl62 (10.1021/JA902010P )
• 3GFE: crystal structure of p38a mitogen-activated protein kinase in complex with a pyrazolopyridinone inhibitor (10.1016/J.BMCL.2009.06.058 )
• 3GI3: crystal structure of a n-phenyl-n'-naphthylurea analog in complex with p38 map kinase (10.1016/J.BMCL.2009.03.104 )
• 3HA8: the complex structure of the map kinase p38/compound 14b (10.1038/NCHEMBIO.211 )
• 3HEC: p38 in complex with imatinib (10.1021/BI100070R )
• 3HEG: p38 in complex with sorafenib (10.1021/BI100070R )
• 3HL7: crystal structure of human p38alpha complexed with sd-0006 (10.1021/BI900655F )
• 3HLL: crystal structure of human p38alpha complexed with ph-797804 (10.1021/BI900655F )
• 3HP2: crystal structure of human p38alpha complexed with a pyridinone compound (10.1016/J.BMCL.2009.08.082 )
• 3HP5: crystal structure of human p38alpha complexed with a pyrimidopyridazinone compound (10.1016/J.BMCL.2009.08.082 )
• 3HRB: p38 kinase crystal structure in complex with small molecule inhibitor (10.1021/JM9008604 )
• 3HUB: human p38 map kinase in complex with scios-469 (10.1021/JA908083E )
• 3HUC: human p38 map kinase in complex with rl40 (10.1021/JA908083E )
• 3HV3: human p38 map kinase in complex with rl49 (10.1021/JM901297E )
• 3HV4: human p38 map kinase in complex with rl51 (10.1021/JM901297E )
• 3HV5: human p38 map kinase in complex with rl24 (10.1021/JM901297E )
• 3HV6: human p38 map kinase in complex with rl39 (10.1021/JM901297E )
• 3HV7: human p38 map kinase in complex with rl38 (10.1021/JM901297E )
• 3HVC: crystal structure of human p38alpha map kinase (10.1016/J.JMB.2009.06.005 )
• 3IPH: crystal structure of p38 in complex with a biphenylamide inhibitor (10.1021/JM9004779 )
• 3ITZ: crystal structure of p38a mitogen-activated protein kinase in complex with a pyrazolopyridazine inhibitor (10.1016/J.BMCL.2010.01.059 )
• 3IW5: human p38 map kinase in complex with an indole derivative (10.1021/JA907795Q )
• 3IW6: human p38 map kinase in complex with a benzylpiperazin-pyrrol (10.1021/JA907795Q )
• 3IW7: human p38 map kinase in complex with an imidazo-pyridine (10.1021/JA907795Q )
• 3IW8: structure of inactive human p38 map kinase in complex with a thiazole- urea (10.1021/JA907795Q )
• 3K3I: p38alpha bound to novel dgf-out compound pf-00215955 (10.1111/J.1747-0285.2009.00884.X )
• 3K3J: p38alpha bound to novel dfg-out compound pf-00416121 (10.1111/J.1747-0285.2009.00884.X )
• 3KF7: crystal structure of human p38alpha complexed with a triazolopyrimidine compound (10.1016/J.BMCL.2009.11.114 )
• 3KQ7: structure of human p38alpha with n-[4-methyl-3-(6-{[2-(1- methylpyrrolidin-2-yl)ethyl]amino}pyridine-3-amido)phenyl]- 2-(morpholin-4-yl)pyridine-4-carboxamide
• 3L8S: human p38 map kinase in complex with cp-547632 (10.1021/JA908083E )
• 3L8X: p38 alpha kinase complexed with a pyrazolo-pyrimidine based inhibitor (10.1016/J.BMCL.2008.03.019 )
• 3LFA: human p38 map kinase in complex with dasatinib
• 3LFB: human p38 map kinase in complex with rl98
• 3LFC: human p38 map kinase in complex with rl99
• 3LFD: human p38 map kinase in complex with rl113
• 3LFE: human p38 map kinase in complex with rl116
• 3LFF: human p38 map kinase in complex with rl166
• 3LHJ: crystal structure of p38a mitogen-activated protein kinase in complex with a pyrazolopyridinone inhibitor. (10.1021/JM100095X )
• 3MGY: mutagenesis of p38 map kinase eshtablishes key roles of phe169 in function and structural dynamics and reveals a novel dfg-out state (10.1021/BI0622221 )
• 3MH0: mutagenesis of p38 map kinase eshtablishes key roles of phe169 in function and structural dynamics and reveals a novel dfg-out state (10.1021/BI0622221 )
• 3MH1: mutagenesis of p38 map kinase establishes key roles of phe169 in function and structural dynamics and reveals a novel dfg-out state 12-may-10 3mh1 1 title (10.1021/BI0622221 )
• 3MH2: mutagenesis of p38 map kinase establishes key roles of phe169 in function and structural dynamics and reveals a novel dfg-out state (10.1021/BI0622221 )
• 3MH3: mutagenesis of p38 map kinase establishes key roles of phe169 in function and structural dynamics and reveals a novel dfg-out state (10.1021/BI0622221 )
• 3MPA: conformational plasticity of p38 map kinase dfg motif mutants in response to inhibitor binding
• 3MPT: crystal structure of p38 kinase in complex with a pyrrole-2- carboxamide inhibitor (10.1016/J.BMCL.2010.05.011 )
• 3MVL: p38 alpha map kinase complexed with pyrrolotriazine inhibitor 7k (10.1021/JM100540X )
• 3MVM: p38 alpha map kinase complexed with pyrrolotriazine inhibitor 7v (10.1021/JM100540X )
• 3MW1: p38 kinase crystal structure in complex with small molecule inhibitor (10.1021/JM200975U )
• 3NEW: p38-alpha complexed with compound 10 (10.1021/CB1002619 )
• 3NNU: crystal structure of p38 alpha in complex with dp1376 (10.1016/J.BMCL.2010.07.134 )
• 3NNV: crystal structure of p38 alpha in complex with dp437 (10.1016/J.BMCL.2010.07.134 )
• 3NNW: crystal structure of p38 alpha in complex with dp802 (10.1016/J.BMCL.2010.07.134 )
• 3NNX: crystal structure of phosphorylated p38 alpha in complex with dp802 (10.1016/J.BMCL.2010.07.134 )
• 3NWW: p38 alpha kinase complexed with a 2-aminothiazol-5-yl-pyrimidine based inhibitor (10.1016/J.BMCL.2010.07.102 )
• 3O8P: conformational plasticity of p38 map kinase dfg motif mutants in response to inhibitor binding
• 3O8T: conformational plasticity of p38 map kinase dfg-motif mutants in response to inhibitor binding
• 3O8U: conformational plasticity of p38 map kinase dfg motif mutants in response to inhibitor binding
• 3OBG: conformational plasticity of p38 map kinase dfg mutants in response to inhibitor binding
• 3OBJ: conformational plasticity of p38 map kinase dfg mutants in response to inhibitor binding
• 3OC1: conformational plasticity of p38 map kinase dfg motif mutants in response to inhibitor binding
• 3OCG: p38 alpha kinase complexed with a 5-amino-pyrazole based inhibitor (10.1016/J.BMCL.2010.10.034 )
• 3OD6: crystal structure of p38alpha y323t active mutant (10.1016/J.JMB.2010.11.023 )
• 3ODY: crystal structure of p38alpha y323q active mutant (10.1016/J.JMB.2010.11.023 )
• 3ODZ: crystal structure of p38alpha y323r active mutant (10.1016/J.JMB.2010.11.023 )
• 3OEF: crystal structure of y323f inactive mutant of p38alpha map kinase (10.1016/J.JMB.2010.11.023 )
• 3OHT: crystal structure of salmo salar p38alpha (10.1016/J.JMB.2011.06.013 )
• 3P4K: the third conformation of p38a map kinase observed in phosphorylated p38a and in solution (10.1016/J.STR.2010.09.015 )
• 3P5K: p38 inhibitor-bound (10.1016/J.BMCL.2011.09.078 )
• 3P78: p38 inhibitor-bound (10.1016/J.BMCL.2011.09.078 )
• 3P79: p38 inhibitor-bound (10.1016/J.BMCL.2011.09.078 )
• 3P7A: p38 inhibitor-bound (10.1016/J.BMCL.2011.09.078 )
• 3P7B: p38 inhibitor-bound (10.1016/J.BMCL.2011.09.078 )
• 3P7C: p38 inhibitor-bound (10.1016/J.BMCL.2011.09.078 )
• 3PG3: human p38 map kinase in complex with rl182
• 3PY3: crystal structure of phosphorylated p38alpha map kinase (10.1074/JBC.M110.203786 )
• 3QUD: human p38 map kinase in complex with 2-amino-phenylamino-benzophenone
• 3QUE: human p38 map kinase in complex with skepinone-l (10.1038/NCHEMBIO.761 )
• 3RIN: p38 kinase crystal structure in complex with small molecule inhibitor (10.1016/J.BMCL.2011.05.114 )
• 3ROC: crystal structure of human p38 alpha complexed with a pyrimidinone compound (10.1016/J.BMCL.2011.05.006 )
• 3S3I: p38 kinase crystal structure in complex with small molecule inhibitor (10.1016/J.BMCL.2012.03.099 )
• 3S4Q: p38 alpha kinase complexed with a pyrazolo-triazine based inhibitor (10.1016/J.BMCL.2011.05.091 )
• 3TG1: crystal structure of p38alpha in complex with a mapk docking partner (10.1126/SCISIGNAL.2002241 )
• 3U8W: crystal structure of p38a mitogen-activated protein kinase in complex with a triazolopyridazinone inhibitor (10.1016/J.BMCL.2011.11.067 )
• 3UVP: human p38 map kinase in complex with a benzamide substituted benzosuberone (10.1021/JM300951U )
• 3UVQ: human p38 map kinase in complex with a dibenzosuberone derivative 16-jan-13 3uvq 1 jrnl title (10.1021/JM301539X )
• 3UVR: human p38 map kinase in complex with km064
• 3ZS5: structural basis for kinase selectivity of three clinical p38alpha inhibitors (10.1107/S090744491201997X )
• 3ZSG: x-ray structure of p38alpha bound to tak-715 (10.1107/S090744491201997X )
• 3ZSH: x-ray structure of p38alpha bound to scio-469 (10.1107/S090744491201997X )
• 3ZSI: x-ray structure of p38alpha bound to vx-745 (10.1107/S090744491201997X )
• 3ZYA: human p38 map kinase in complex with 2-amino-phenylamino- dibenzosuberone (10.1038/NCHEMBIO.761 )
• 4A9Y: p38alpha map kinase bound to cmpd 8 (10.1016/J.BMCL.2012.04.116 )
• 4AA0: p38alpha map kinase bound to cmpd 2 (10.1016/J.BMCL.2012.04.116 )
• 4AA4: p38alpha map kinase bound to cmpd 22 (10.1016/J.BMCL.2012.04.116 )
• 4AA5: p38alpha map kinase bound to cmpd 33 (10.1016/J.BMCL.2012.04.116 )
• 4AAC: p38alpha map kinase bound to cmpd 29 (10.1016/J.BMCL.2012.04.116 )
• 4DLI: human p38 map kinase in complex with rl87 (10.1371/JOURNAL.PONE.0039713 )
• 4DLJ: human p38 map kinase in complex with rl163 (10.1371/JOURNAL.PONE.0039713 )
• 4E5A: the w197a mutant of p38a map kinase (10.1016/J.JMB.2012.10.007 )
• 4E5B: structure of p38a map kinase without bog (10.1016/J.JMB.2012.10.007 )
• 4E6A: p38a-pia23 complex (10.1016/J.JMB.2012.10.007 )
• 4E6C: p38a-perifosine complex (10.1016/J.JMB.2012.10.007 )
• 4E8A: the crystal structure of p38a map kinase in complex with pia24 (10.1016/J.JMB.2012.10.007 )
• 4EH2: human p38 map kinase in complex with np-f1 and rl87 (10.1038/NCHEM.1506 )
• 4EH3: human p38 map kinase in complex with np-f2 and rl87 (10.1038/NCHEM.1506 )
• 4EH4: human p38 map kinase in complex with np-f3 and rl87 (10.1038/NCHEM.1506 )
• 4EH5: human p38 map kinase in complex with np-f4 and rl87 (10.1038/NCHEM.1506 )
• 4EH6: human p38 map kinase in complex with np-f5 and rl87 (10.1038/NCHEM.1506 )
• 4EH7: human p38 map kinase in complex with np-f6 and rl87 (10.1038/NCHEM.1506 )
• 4EH8: human p38 map kinase in complex with np-f7 and rl87 (10.1038/NCHEM.1506 )
• 4EH9: human p38 map kinase in complex with np-f11 and rl87 (10.1038/NCHEM.1506 )
• 4EHV: human p38 map kinase in complex with np-f10 and rl87 (10.1038/NCHEM.1506 )
• 4EWQ: human p38 alpha mapk in complex with a pyridazine based inhibitor (10.1021/ACS.JMEDCHEM.9B00058 )
• 4F9W: human p38alpha mapk in complex with a novel and selective small molecule inhibitor (10.1371/JOURNAL.PONE.0066226 )
• 4F9Y: human p38 alpha mapk in complex with a novel and selective small molecule inhibitor (10.1371/JOURNAL.PONE.0066226 )
• 4FA2: human p38 alpha mitogen-activated kinase in complex with sb239063 (10.1371/JOURNAL.PONE.0066226 )
• 4GEO: p38a map kinase def-pocket penta mutant (m194a, l195a, h228a, i229a, y258a)
• 4KA3: structure of map kinase in complex with a docking peptide (10.1007/S11427-013-4494-0 )
• 4KIN: crystal structure of mitogen-activated protein kinase 14 (p38-h5) complex with 5-(2-chlorophenyl)-n-(5-(cyclopropylcarbamoyl)-2- methylphenyl)-2-thiophenecarboxamide (10.1016/J.BMCL.2013.05.047 )
• 4KIP: crystal structure of mitogen-activated protein kinase 14 (p38-h5) complex with 2-(2-chlorophenyl)-n-(5-(cyclopropylcarbamoyl)-2- methylphenyl)-1,3-thiazole-5-carboxamide (10.1016/J.BMCL.2013.05.047 )
• 4KIQ: crystal structure of mitogen-activated protein kinase 14 (p38-h5) complex with ethyl 6-((5-(cyclopropylcarbamoyl)-2-methylphenyl) carbamoyl)-1h-indole-1-carboxylate (10.1016/J.BMCL.2013.05.047 )
• 4L8M: human p38 map kinase in complex with a dibenzoxepinone (10.1021/JM401276H )
• 4LOO: structural basis of autoactivation of p38 alpha induced by tab1 (monoclinic crystal form) (10.1038/NSMB.2668 )
• 4LOP: structural basis of autoactivation of p38 alpha induced by tab1 (tetragonal crystal form) (10.1038/NSMB.2668 )
• 4LOQ: structural basis of autoactivation of p38 alpha induced by tab1 (tetragonal crystal form with bound sulphate) (10.1038/NSMB.2668 )
• 4R3C: crystal structure of p38 alpha map kinase in complex with a novel isoform selective drug candidate (10.1021/ACSCHEMNEURO.5B00002 )
• 4TYH: ternary complex of p38 and mk2 with a p38 inhibitor
• 4ZTH: structure of human p38amapk-arylpyridazinylpyridine fragment complex used in inhibitor discovery (10.1021/ACS.JMEDCHEM.9B00058 )
• 5ETA: structure of mapk14 with bound the kim domain of the toxoplasma protein gra24 (10.1016/J.STR.2016.10.011 )
• 5ETC: structure of inactive mapk14 with ordered activation loop
• 5ETF: structure of dead kinase mapk14 with bound the kim domain of mkk6 (10.1016/J.STR.2016.10.011 )
• 5ETI: structure of dead kinase mapk14
• 5LAR: crystal structure of p38 alpha mapk14 in complex with vpc00628 (10.1039/C6MD00241B )
• 5ML5: human p38alpha mapk in complex with imidazolyl pyridine inhibitor 11b (10.3390/MOLECULES22040522 )
• 5MTX: dibenzooxepinone inhibitor 12b in complex with p38 mapk (10.1021/ACS.JMEDCHEM.7B00745 )
• 5MTY: dibenzosuberone inhibitor 8e in complex with p38 mapk (10.1021/ACS.JMEDCHEM.7B00745 )
• 5MZ3: p38 alpha mutant c162s in complex with cmpd2 [n-(4-methyl-3-(4,4,5,5- tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-3-(trifluoromethyl) benzamide] (10.1016/J.BMCL.2017.10.047 )
• 5N63: crystal structure of p38alpha in complex with lipid pocket ligand 9c (10.1371/JOURNAL.PONE.0184627 )
• 5N64: crystal structure of p38alpha in complex with lipid pocket ligand 9g (10.1371/JOURNAL.PONE.0184627 )
• 5N65: crystal structure of p38alpha in complex with lipid pocket ligand 9h (10.1371/JOURNAL.PONE.0184627 )
• 5N66: crystal structure of p38alpha in complex with lipid pocket ligand 9j (10.1371/JOURNAL.PONE.0184627 )
• 5N67: crystal structure of p38alpha in complex with lipid pocket ligand 9l (10.1371/JOURNAL.PONE.0184627 )
• 5N68: crystal structure of p38alpha in complex with lipid pocket ligand 9m (10.1371/JOURNAL.PONE.0184627 )
• 5NZZ: crystal structure of phosphorylated p38amapk in complex with tab1 (10.1172/JCI.INSIGHT.121144 )
• 5O8U: covalent inhibitor 4b bound to the lipid pocket of p38alpha mutant s252c (10.1002/ANIE.201706345 )
• 5O8V: covalent inhibitor 4a bound to the lipid pocket of p38alpha mutant s251c (10.1002/ANIE.201706345 )
• 5O90: crystal structure of a p38alpha t185g mutant in complex with tab1 peptide. (10.1128/MCB.00409-17 )
• 5OMG: p38alpha in complex with pyrazolobenzothiazine inhibitor coxp4m12 (10.1016/J.BBRC.2019.02.063 )
• 5OMH: p38alpha in complex with pyrazolobenzothiazine inhibitor coxh11 (10.1016/J.BBRC.2019.02.063 )
• 5R8U: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n05703b in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R8V: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n09139b in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R8W: pandda analysis group deposition form1 map kinase p38-alpha -- fragment k00283c in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R8X: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n11396a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R8Y: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n08078b in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R8Z: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n01381c in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R90: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n11145a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R91: pandda analysis group deposition form1 map kinase p38-alpha -- fragment kcl057 in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R92: pandda analysis group deposition form1 map kinase p38-alpha -- fragment kcl063 in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R93: pandda analysis group deposition form1 map kinase p38-alpha -- fragment kcl077 in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R94: pandda analysis group deposition form1 map kinase p38-alpha -- fragment kcl081 in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R95: pandda analysis group deposition form1 map kinase p38-alpha -- fragment kcl093 in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R96: pandda analysis group deposition form1 map kinase p38-alpha -- fragment kcl095 in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R97: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13662a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R98: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n14109a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R99: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13619a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9A: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13838a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9B: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13866a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9C: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n14074a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9D: pandda analysis group deposition form1 map kinase p38-alpha -- fragment s00888c in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9E: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13693a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9F: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13724a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9G: pandda analysis group deposition form1 map kinase p38-alpha -- fragment pc587 in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9H: pandda analysis group deposition form1 map kinase p38-alpha -- fragment tcj658 in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9I: pandda analysis group deposition form1 map kinase p38-alpha -- fragment tcj795 in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9J: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n14231a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9K: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n14246a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9L: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n14274a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9M: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13418a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9N: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13421a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9O: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n06122b in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9P: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13430a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9Q: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n07422b in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9R: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13413a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9S: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13470a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9T: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13477a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9U: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13475a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9V: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13596a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9W: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13598a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9X: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13611a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9Y: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13619a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5R9Z: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13502a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5RA0: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n13421a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5RA1: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n08141b in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5RA2: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n09036b in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5RA3: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n10836b in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5RA4: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n11337a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5RA5: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n11302a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5RA6: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n11338a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5RA7: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n11351a in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5RA8: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n05711b in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5RA9: pandda analysis group deposition form1 map kinase p38-alpha -- fragment n08051b in complex with map kinase p38-alpha (10.1021/ACS.JMEDCHEM.0C00403 )
• 5TBE: human p38alpha map kinase in complex with dibenzosuberone compound 2 (10.1002/ANIE.201701185 )
• 5TCO: human p38 map kinase in complex with dibenzosuberone compound 1 (10.1002/ANIE.201701185 )